Abstract: An oligomer or polymer comprising a first repeat unit and a second repeat unit that may be the same or different, the first repeat unit having formula (I): wherein each E independently represents optionally substituted nitrogen or optionally substituted phosphorus, with the proviso that at least one E is optionally substituted phosphorus; each Ar1, Ar2 and Ar3 is the same or different and independently represents an optionally substituted aryl or heteroaryl; n is 0-3; and in the case of unsubstituted nitrogen and phosphorus, the second repeat unit is directly conjugated to the first repeat unit.

Abstract: The present invention relates to the use of laser-engraved printing forms for printing using printing inks in a gravure printing process, where the printing inks are pigmented with flake-form effect pigments, to a corresponding gravure printing process, and to a printing ink.

Abstract: The invention relates to methods of manipulating immobilised carbohydrates by derivatisation. Depending on the nature of the derivatisation, the carbohydrate may thereby be more easily detected and/or identified or handled. In particular, the invention relates to methods of preparing a reactive sugar comprising the steps of: i) providing a sample comprising a reducing sugar; ii) providing a solid support covalently attached to a linker comprising a capture group comprising an —NH2 group, wherein said linker optionally is attached to said solid support via a spacer; iii) reacting said reducing sugar with said —NH2 group, thereby obtaining an immobilised sugar; iv) reacting free —NH2 groups with a capping agent, wherein the capping agent comprises a reactive group capable of reacting with an —NH2 group; and v) reducing C?N bonds with a reducing agent, thereby obtaining an reactive sugar of the structure SugarCHn-NH— linked to a solid support via a linker and optionally a spacer, wherein n is 1 or 2.

Abstract: Compounds of formula I: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Abstract: This invention concerns compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3 -yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof. In another aspect, this invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to an organic electronic (OE) device, in particular a transistor, comprising an interlayer between the gate insulator and the gate electrode, to novel processes for preparing the device, and to dielectric materials for use in the interlayer.

Abstract: The invention relates to the use of ?-amino acid derivatives for improving the solubility of poorly soluble substances in water or aqueous solutions and to mixtures and preferred preparations.

Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.

Abstract: A method of making a liquid crystal device is provided, the method comprising (i) providing a cell containing a mixture of a liquid crystal and pre-polymer (ii) applying a stimulus to arrange the liquid crystal in a first predetermined state and (iii) subsequent to, or contemporaneously with, step (ii), causing the pre-polymer to form polymer when the liquid crystal is in a second predetermined state, wherein steps (ii) and (iii) are performed a plurality of times.

Abstract: The present invention relates to an opto-electronic device comprising a layer comprising a polymer containing fluorine-containing groups, where an adhesive fluorine-fluorine interaction exists at least between some of the fluorine-containing groups of the layer. The invention is furthermore directed to the use of the opto-electronic device and to a process for the production thereof.

Abstract: The present invention relates to a compound of the formula (1) and (2) The invention further relates to a process to produce the compound. The invention additionally relates and an electronic device containing the compound of the formula (1) or (2). The electronic device can be an organic electroluminescence devices, particularly a blue emitting device, in which compounds are used as host materials or dopants in the emitting layer and/or as hole transport materials and/or as electron transport materials.

Abstract: The invention relates to particles which have been functionalised by means of an inertised reactive group, i.e. by means of specific reversibly blocked isocyanate groups, and whose inertisation can be reversed by means of an external influence.

Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Abstract: Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

Abstract: An electroluminescent composition is provided comprising: (a) a compound of the general chemical formula (I): wherein M is lithium, sodium, potassium, rubidium, caesium, beryllium, magnesium, calcium, strontium, barium, copper, silver, gold, zinc, boron, aluminum, gallium, indium, germanium, tin, antimony, lead, manganese, iron, ruthenium, osmium, cobalt, rhodium, iridium, nickel, palladium, platinum, cadmium or chromium; n is the valence of M; and R1, R2 and R3 can be the same or different, and are selected from hydrogen, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic, heterocyclic or polycyclic ring structure, a fluorocarbon, a halogen or a nitrile group; and (b) a suitable dopant. The composition may be used in forming electroluminescent devices.

Abstract: The present invention relates to a liquid-crystalline medium having high twist, to the use thereof for electro-optical purposes, and to displays containing this medium.

Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.

Abstract: The invention relates to pyran derivatives of the formula I and to a process and intermediates for their preparation and derivatisation, and to the use thereof in liquid-crystalline media.

Abstract: The invention relates to a pigment mixture consisting of at least two constituents, constituent A being uncoated, monocoated or multicoated glass lamellae, and constituent B being nacreous pigments based on phyllosilicates, SiO2 lamellae, Fe2O3 lamellae or Al2O3 lamellae. The invention also relates to the use of said pigment mixture, inter alia, in paints, dyes, especially printing inks, plastics, powder paints, pastes and cosmetic formulations.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).